Drug research

CT1812

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Study Drug; Study Drug Active; zervimesine

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEGNCT04735536	Cognition Therapeutics	Phase 2	Completed	2023-04-26Actual
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.NCT03507790	Cognition Therapeutics	Phase 2	Completed	2024-05-29Actual
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesNCT05225415	Cognition Therapeutics	Phase 2	Completed	2024-11-25Actual
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseaseNCT05531656	Cognition Therapeutics	Phase 2	Active not recruiting	2027-05-31Estimated

Cognition TherapeuticsCompletedPrimary completion: 2023-04-26 · Actual

Trial details

Cognition TherapeuticsCompletedPrimary completion: 2024-05-29 · Actual

Trial details

Cognition TherapeuticsCompletedPrimary completion: 2024-11-25 · Actual

Trial details

Cognition TherapeuticsActive not recruitingPrimary completion: 2027-05-31 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.